Form 8-K - Current report:
SEC Accession No. 0001193125-26-084309
Filing Date
2026-03-02
Accepted
2026-03-02 08:16:28
Documents
18
Period of Report
2026-03-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d101756d8k.htm   iXBRL 8-K 40596
2 EX-5.1 d101756dex51.htm EX-5.1 9055
3 EX-99.1 d101756dex991.htm EX-99.1 9195
4 EX-99.2 d101756dex992.htm EX-99.2 14422
8 GRAPHIC g101756dsp19a.jpg GRAPHIC 6682
9 GRAPHIC g101756dsp19b.jpg GRAPHIC 11289
10 GRAPHIC g101756g0301221517365.jpg GRAPHIC 3727
  Complete submission text file 0001193125-26-084309.txt   234637

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ntla-20260302.xsd EX-101.SCH 2845
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20260302_lab.xml EX-101.LAB 17992
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20260302_pre.xml EX-101.PRE 11257
20 EXTRACTED XBRL INSTANCE DOCUMENT d101756d8k_htm.xml XML 3630
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 26703583
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)